OBJECTIVES

: NSCLC accounts for 80% of all lung cancers. As molecular pathways in NSCLC and mutations in these pathways are revealed, targeted therapies specific to these mutations have been developed. These therapies, has led to an increase in the life span, progression free survival and quality of life for metastatic patients. The incidence rate of NSCLC in Turkey is 59.3 in 100,000 in men while 10 in 100,000 in women. The purpose of this study is to analyze the targeted therapies in NSCLC market and to identify their registration and reimbursement status.

METHODS

: The study was undertaken from the Turkish health care payer perspective (SSI). An Excel sheet was formed to calculate the ratios and results. Resource utilization data were obtained from MoH List of Registered Drugs June 2018, RxMediapharma, SSI Health Implementation Guideline Annex 4/A and Rx Media Pharma 2018.

RESULTS

: There are 17 targeted NSCLC therapies in global market. These are subclassified as ALK, EGFR, VEGF, BRAF, PDL-1 mutation drugs. 13 of them (76%) are registered in Turkey. 2 of them are still in the registration process. 10 of these drugs (59%) are reimbursed by SSI. 5 of these reimbursed therapies (50%) were granted reimbursement via Managed Entry Agreements by Alternative Reimbursement Committee. Maximum duration of the reimbursement evaluation process was 22 months and the shortest duration was 3 months. Main companies in this therapeutic area respectively are Roche, Novartis and Astra Zeneca.

CONCLUSIONS

: New targeted therapies for NSCLC constitute a significant market in Turkey and is one of the most reimbursement granted therapeutic groups in 2018.